荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 04-30 16:08:13

100.600

+0.500

+0.50%

最高103.500	最低98.500	成交量283.07万
今开100.100	昨收100.100	日振幅5.00%
总市值566.99亿	流通市值209.83亿	总股本5.64亿
成交额2.86亿	换手率1.36%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":100.6,"timestamp":1777536493009,"preClose":100.1,"halted":0,"volume":2830700,"delay":0,"changeRate":0.004995004995004995,"floatShares":208581239,"shares":563608243,"eps":1.4797421493042497,"marketStatus":"休市中","change":0.5,"latestTime":"04-30 16:08:13","open":100.1,"high":103.5,"low":98.5,"amount":285980415,"amplitude":0.04995,"askPrice":100.8,"askSize":3000,"bidPrice":100.6,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":2.6777574525980947,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":100.1,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.8218096500124904,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":129.31,"timestamp":1777532400000,"preClose":131,"halted":0,"volume":8390800,"delay":0,"premium":"-32.18"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2632493046","title":"每周股票复盘：荣昌生物（688331）Q1净利增229.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632493046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632493046?lang=zh_cn&edition=full","pubTime":"2026-05-02 01:26","pubTimestamp":1777656371,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，荣昌生物报收于129.31元，较上周的133.03元下跌2.8%。本周，荣昌生物4月28日盘中最高价报139.98元。股本股东变化截至2026年3月31日，荣昌生物股东户数为1.97万户，较2月28日增加2264户，增幅达12.97%。业绩披露要点荣昌生物2026年一季报显示，主营收入6.56亿元，同比增长24.76%；归母净利润3.28亿元，同比上升229.06%；扣非净利润-3499.1万元，同比改善86.12%；负债率为46.66%，毛利率为82.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2488822045.USD","688331","LU1969619763.USD","09995","BK1583","LU2328871848.SGD","LU1064130708.USD","LU1064131003.USD","BK0239","BK1161","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578474","title":"荣昌生物（688331）2026年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631578474?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:54","pubTimestamp":1777503282,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期荣昌生物发布2026年一季报。根据财报显示，荣昌生物营收净利润同比双双增长。截至本报告期末，公司营业总收入6.56亿元，同比上升24.76%，归母净利润3.28亿元，同比上升229.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161848987","title":"荣昌生物2026年第一季度营收6.56亿元，非GAAP净利润3.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161848987","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161848987?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:43","pubTimestamp":1777383794,"startTime":"0","endTime":"0","summary":"据公司披露，荣昌生物2026年第一季度实现营业收入约6.56亿元，同比增长24.76%。同期非GAAP净利润约3.28亿元，而上年同期则为净亏损约2.54亿元，经营表现大幅好转。经营活动产生的现金流量净额约0.11亿元，相较于上年同期的-1.88亿元也显著改善。报告期内，研发投入约2.10亿元，同比下降36.19%，占营业收入的31.98%，较去年同期水平下降30.55个百分点。研发支出减少主要与产品技术授权等因素相关，也在一定程度上推动了公司整体利润转正。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荣昌生物2026年第一季度营收6.56亿元，非GAAP净利润3.28亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175332581","title":"荣昌生物2025年营收同比增长89.5%至32.42亿元，核心产品驱动扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1175332581","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175332581?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:51","pubTimestamp":1777366299,"startTime":"0","endTime":"0","summary":"荣昌生物在截至2025年12月31日止年度实现收入32.42亿元人民币，较2024年的17.10亿元增长89.5%。报告期内毛利从13.67亿元增长至28.16亿元，年内收益7.10亿元，而2024年同期为亏损14.68亿元，盈利水平大幅改善。综合来看，荣昌生物在2025年度依靠创新药物商业化与多条研发管线的进展实现营收和利润的同步提升，显示出其在自身免疫及肿瘤等领域的积累正逐步转化为市场份额与财务回报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"荣昌生物2025年营收同比增长89.5%至32.42亿元，核心产品驱动扭亏为盈","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137868631","title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1137868631","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137868631?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:48","pubTimestamp":1777366101,"startTime":"0","endTime":"0","summary":"4月28日，$荣昌生物(09995)$公告称，2026年第一季度实现营业收入6.56亿元，同比增长24.76%；归属于上市公司股东的净利润为3.28亿元，同比扭亏为盈。业绩变动主要系商业化产品销售收入持续增加，以及产品技术授权导致研发投入减少，认股权证公允价值变动所致。小财注：公司Q1净利润3.28亿，2025年Q4净利润12.6亿，据此计算，Q1净利润环比下降73%。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","09995","LU2148510915.USD","688331","LU2488822045.USD","LU1064130708.USD","BK0239","LU1969619763.USD","LU2328871848.SGD","LU1064131003.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397093","title":"荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397093","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:04","pubTimestamp":1777298696,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，荣昌生物报收于135.05元，较前一交易日上涨1.52%，最新总市值为762.33亿元。近日，荣昌生物发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00参加由上海证券交易所组织举办的上述集体业绩说明会，通过上证路演中心网络文字互动方式与投资者交流。公司将就2025年度经营成果、财务状况等投资者关注的问题进行回应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","LU2148510915.USD","BK1161","LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD","09995","BK1574","688331","BK1583","LU1064131003.USD","LU1064130708.USD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009846","title":"汇添富基金增持荣昌生物(09995)7.9万股 每股作价约113.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009846","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629009846?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:09","pubTimestamp":1777028987,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，汇添富基金增持荣昌生物(09995)7.9万股，每股作价113.7788港元，总金额约为898.85万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131003.USD","LU2488822045.USD","BK1574","09995","LU2328871848.SGD","BK1583","LU2148510915.USD","BK1161","EWH","688331","LU1969619763.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["USL","DBE","BK1589","LU2097828805.USD","DRIP","LU2097828631.EUR","DRLL","BWET","01530","PXJ","OILU","LU2097828474.EUR","03692","IEO","LU1969619763.USD","UGA","VDE","BK1593","BNO","06978","BK4570","GUSH","BK1583","VXUS","BK1574","DUG","LU2097828714.EUR","159992","HK0000165453.HKD","IXC","LU0455707207.USD","DIG","LU2328871848.SGD","OILT","09995","DBO","LU2488822045.USD","BK1161","BK1191","LU2242644610.SGD","OIH","LU0502904849.HKD","USE","ERX","OILK","USOI","DBC","01801","LU2097828557.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101463778","title":"异动解读 | 荣昌生物盘中大跌5.19%，多重利好兑现后股价高位回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1101463778","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101463778?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:45","pubTimestamp":1776908718,"startTime":"0","endTime":"0","summary":"荣昌生物（09995.HK）今日盘中股价出现大幅下跌，跌幅达5.19%，引起市场关注。消息面上，公司近期利好密集释放，包括已收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款，以及其全球首创PR-ADC载荷回收平台在AACR大会上披露的超预期核心数据。然而，在前期A股股价一周内涨幅达10.8%、触及近一年新高后，这些利好因素已被市场充分消化。与此同时，南向资金近20个交易日累计净减持467万股，显示出资金持续流出的态势。综合来看，在前期涨幅较大、利好已充分释放叠加资金持续流出的背景下，公司港股股价延续了高位回调的态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703962","title":"百济、信达、贝达、荣昌生物...盈利Biotech增至17家","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703962","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703962?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:54","pubTimestamp":1776772440,"startTime":"0","endTime":"0","summary":"Biotech似乎终于集体熬到了“上岸”时刻。其中最受关注的自然是百济和信达。百济成立15年后，2025年归母净利润达到14.22亿元；信达生物实现近8.14亿元净利润，正式扭亏为盈。百济神州、微芯生物、迈博药业、信达生物、上海谊众、贝达药业、艾力斯等公司的产品销售收入占比都超过90%。荃信生物2025年净利润3.07亿元，8.07亿元总营收里，7.23亿元来自BD收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-04-21/doc-inhvhmhw6117856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","BK4585","LU1064131003.USD","BK4581","XBI","LU1969619763.USD","09995","688331","BK1574","LU2488822045.USD","BK0239","LU2328871848.SGD","BK4588","LU2148510915.USD","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377970","title":"万家基金黄兴亮旗下万家行业优选一季报最新持仓，重仓荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629377970?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:23","pubTimestamp":1776720184,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日万家基金旗下黄兴亮管理的万家行业优选混合型基金(LOF)公布一季报，近1年净值增长率21.98%。与上一季度相比，该基金前十大重仓股新增科大讯飞；其中荣昌生物持仓占比8.84%，为该基金第一大重仓股；圣邦股份等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100010049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2328871848.SGD","LU1969619763.USD","LU1064131003.USD","688331","09995","LU2148510915.USD","BK0239","BK1161","LU1064130708.USD","BK1583","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275136","title":"每周股票复盘：荣昌生物（688331）获艾伯维6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275136","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275136?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:30","pubTimestamp":1776540626,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，荣昌生物报收于150.11元，较上周的135.48元上涨10.8%。本周，荣昌生物4月16日盘中最高价报156.79元，股价触及近一年最高点。荣昌生物当前最新总市值847.34亿元，在生物制品板块市值排名1/51，在两市A股市值排名235/5198。公司公告汇总荣昌生物制药（烟台）股份有限公司宣布，已收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款。该协议于2026年3月10日生效，艾伯维获得了RC148在大中华区以外地区的开发、生产和商业化独家权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","LU2488822045.USD","BK1574","LU2148510915.USD","BK0239","BK1161","BK1583","09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627254292","title":"港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627254292","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627254292?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:01","pubTimestamp":1776301266,"startTime":"0","endTime":"0","summary":"【重大事项】宁德时代(03750)拟投资 300 亿元设立全资子公司 打造新能源矿产平台美格智能(03268)拟投资3亿元于AI研发及先进制造产业项目并签署投资协议力勤资源(02245)：印尼镍矿政策变动不影响正常经营 与合作伙伴保持良好合作关系确保Obi项目稳定运行中远海能(01138)拟10.18亿元建造两艘巴拿马型原油轮荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"05d74946e1a2924d42dd26ed36b9a988","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1051768304.USD","LU1960683339.HKD","LU0823437842.USD","LU0561508036.HKD","LU1481107354.HKD","LU0823397285.USD","LU0051755006.USD","LU1719994722.HKD","LU2152927971.USD","LU0880133367.SGD","01138","01810","LU0048388663.USD","LU2148510915.USD","LU1831875114.USD","LU1956131251.USD","LU1939255532.USD","LU2348774022.SGD","LU2097828474.EUR","LU2257852520.SGD","LU0259732245.USD","LU0540923850.HKD","LU0405327494.USD","LU2298322129.HKD","BK1166","LU0543330483.HKD","000333","HXXD.SI","LU0314109678.HKD","LU1993786604.SGD","LU1880383440.USD","LU0823041008.USD","LU0823426480.USD","01898","LU0456846285.SGD","LU0516423091.SGD","LU1048596156.SGD","IE00B8HQ1Z84.USD","SG9999000459.SGD","LU1781817850.SGD","LU0345776255.USD","LU0650527681.SGD","LU0469268626.HKD","LU1102505762.USD","LU2298064838.USD","LU0348825331.USD","LU0918141887.USD","LU0231483743.USD","LU0823040885.USD","00753","HK0000286598.CNH","LU0261950470.USD","LU3063872942.SGD","HK0000181138.USD","LU0149534421.HKD","HK0000181112.HKD","LU1064131003.USD","02465","LU1188198961.HKD","LU2506951792.HKD","LU2424517915.HKD","SBHMY","LU0449515922.USD","03268","LU1868838027.USD","LU0149721374.USD","BK1502","LU0700851271.USD","603906","LU0823414551.USD","LU0516423174.USD","LU0128522157.USD","LU0823038988.USD","LU2580892862.HKD","LU0164872284.USD","SG9999014674.SGD","LU0326948709.USD","SG9999002828.SGD","LU0359202008.SGD","LU0449509016.USD","BK4526","LU0327786744.USD","LU1105468828.SGD","LU0708995583.HKD","BK1607","LU1023057109.AUD","LU2476274308.USD","LU2097828805.USD","LU1251922891.USD","LU0214875030.USD","LU1997245094.SGD","LU1039395188.USD","SG9999001093.SGD","SGXZ49509284.SGD","300750","LU0072462343.USD","LU1048588211.SGD","LU0675040207.SGD","SG9999001903.USD","LU1255011170.USD","LU0918141705.HKD","BK4588","LU0359201612.USD","LU2097828714.EUR","LU0049853897.USD","LU2495084118.USD","LU0651946864.USD","LU1997244956.HKD","IE00B543WZ88.USD","01093","IE00B8L5B284.USD","LU0823413587.USD","LU1720050803.USD","LU2580892789.USD","LU0531971595.HKD","LU1580142542.USD","LU0871576103.HKD","LU0516422440.USD","LU0828237510.HKD","LU1102505929.USD","LU2348773727.SGD","LU0254981946.USD","LU1807302812.USD","LU1820825898.SGD","LU2360107325.USD","BK1116","LU0211977185.USD","LU0164880469.USD","LU0348735423.USD","LU0823397103.USD","CCOZY","LU0605514214.HKD","LU1880383366.USD","LU1051769294.HKD","LU0499858602.USD","LU2399975544.HKD","LU2506952253.HKD","LU0370786039.SGD","03908","SG9999003461.SGD","LU0672654166.SGD","BK0224","LU1515016050.SGD","LU1721428347.USD","02186","LU2125910500.SGD","LU2778985437.USD","00670","LU0320764599.SGD","LU1934453819.USD","LU1242518857.USD","LU2087589342.USD","SG9999001689.USD","MIUmain","BK4519","LU0509642566.USD","LU0823413660.USD","LU0405327148.USD","IE00BZ199S13.USD","LU1961090484.USD","LU0345775950.USD","02245","600026","LU0269904917.USD","LU1770036033.HKD","LU0531970944.HKD","LU2506952410.USD","06656","LU0228659784.USD","LU0417516738.SGD","688331","BK1149","02298","LU2039709279.SGD","LU0312595415.SGD","LU0505663152.USD","002881","LU0516422952.EUR","LU0067412154.USD","BK1535","LU1303224171.USD","LU0463099449.HKD","LU0594300419.USD","LU2294711713.HKD","LU0307460666.USD","LU0417516902.SGD","SGXZ81163826.USD","LU0593848301.USD","BK4585","81810","LU0611395673.USD","BK1506","601995","BK4141","LU2153592121.USD","06613","LU0348816934.USD","LU0607220059.USD","LU0588546209.SGD","LU0188438112.USD","LU1981816686.USD","LU0039217434.USD","LU0823414478.USD","LU0143863198.USD","LU1152091168.USD","LU0572944931.SGD","LU0047713382.USD","LU2449936058.SGD","LU0797268264.HKD","LU0084288322.USD","LU0502904849.HKD","LU2249611893.SGD","LU1808992512.USD","LU0106252389.USD","LU1064130708.USD","LU0107464264.USD","LU0169518387.USD","01177","SG9999000327.SGD","LU2238339852.HKD","LU0043850808.USD","LU0072913022.USD","LU0210526637.USD","IE00BD6J9T35.USD","BK1575","LU0499858438.USD","LU1770034418.SGD","IE0032431581.USD","LU0441854154.USD","LU0235996351.USD","XIACY","LU0634319403.HKD","601111","LU0132412106.USD","LU2125910849.SGD","09995","LU2294711473.HKD","LU1861219969.SGD","LU1868837565.USD","LU0979878070.USD","FXCNY","LU0029875118.USD","02556","LU2097828557.USD","HK0000165453.HKD","IE00B3M56506.USD","LU0821914370.USD","BK1521","LU0594300179.USD","03750","LU0124384867.USD","IE0003795394.USD","IE00B5MMRT66.SGD","LU0048580855.USD","LU0244354667.USD","LU2476274720.SGD","LU1282648689.USD","BK1615","LU0724618433.USD","BK1589","LU0320764755.SGD","LU1979443071.USD","LU1242518931.SGD","SG9999001846.SGD","LU0455707207.USD","LU1008478684.HKD","LU2328871848.SGD","LU1978683503.SGD","LU0106259558.USD","LU1997245177.USD","LU2097828631.EUR","LU0164865239.USD","LU0828237940.HKD","LU1813983027.USD","LU1655091616.SGD","02038","LU1152091754.HKD","LU0302445910.USD","06936","LU0828238088.HKD","LU1323998911.USD","LU0251143458.SGD","LU0823039010.USD","LU0011963245.USD","LU0117841782.USD","LU1861214812.USD","600115","BK1193","LU2045819591.USD","LU0054450605.USD","LU0328353924.USD","LU2242644610.SGD","LU0348814723.USD","LU2357125470.USD","LU1969619763.USD","BK1618","IE0003851619.USD","LU1146622755.USD","LU2477742899.HKD","LU0456827905.SGD","LU0052750758.USD","LU2275660780.HKD","SG9999002463.SGD","LU1328277881.USD","BK1523","LU0140636845.USD","IE0034224299.USD","LU0048575426.USD","LU1794554557.SGD","LU0181495838.USD","BK1610","LU0143863784.USD","EVS.SI","LU0516422366.SGD","LU2226246903.HKD","LU1769817179.HKD","LU2506952337.HKD","LU0348805143.USD","LU0192582467.USD","300433","601898","LU0106959298.USD","LU0359201885.HKD","LU0348827113.USD","LU0501845795.SGD","LU2289578879.USD","LU0165289439.USD","00300","LU0651947912.USD","IE00B29SXG58.USD","LU2153591404.USD","LU0823426308.USD","002352","08279","IE00BPRC5H50.USD","LU0326950275.SGD","LU1769817096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627256069","title":"智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率","url":"https://stock-news.laohu8.com/highlight/detail?id=2627256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627256069?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:41","pubTimestamp":1776296486,"startTime":"0","endTime":"0","summary":"探索词元交易等新型交易模式，构建以词元为基础，可量化、可定价的数据集价值体系。将进出口银行的境外贷款杠杆率由3上调至3.5。截至收盘，暗盘交易显示报价578港元，较招股价324.2港元上涨78.29%，每手100股，不计手续费，每手赚25380港元。归属于上市公司股东的净利润为207","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03750","BK1583","01177","601995","LU1023057109.AUD","LU1993786604.SGD","SG9999002828.SGD","BK1116","BK1147","LU1960683339.HKD","LU1008478684.HKD","LU0359201612.USD","BK1501","06656","BK1516","LU2328871848.SGD","LU1807302812.USD","LU0359202008.SGD","08279","BK1574","BK1161","LU0067412154.USD","BK1610","09995","300750","SBHMY","688331","02245","BK4588","BK4585","LU1152091168.USD","LU1969619763.USD","BK1190","LU0880133367.SGD","03908","BK1564","LU1152091754.HKD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627340291","title":"荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2627340291","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627340291?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:46","pubTimestamp":1776242798,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，于2026年1月12日，本公司与艾伯维就RC148签署独家授权许可协议，该协议于2026年3月10日生效。根据协议，艾伯维将获得RC148在大中华区以外地区的开发、生产和商业化的独家权利。本公司董事会欣然宣布，本公司已就RC148的独家授权许可协议从艾伯维收到6.5亿美元的首付款。目前双方的合作进展顺利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","09995","BK1574","LU1064130708.USD","688331","LU2148510915.USD","LU1969619763.USD","BK1161","BK0239","BK1583","LU1064131003.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540852","title":"港股创新药板块午后持续走高，荣昌生物涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540852","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540852?lang=zh_cn&edition=full","pubTime":"2026-04-15 13:10","pubTimestamp":1776229832,"startTime":"0","endTime":"0","summary":"4月15日，港股创新药板块午后持续走高，荣昌生物涨近10%，君实生物涨超5%，诺诚健华、信达生物、复星医药跟涨。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705735216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705735216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2488822045.USD","BK4588","159992","LU1064131003.USD","BK1161","LU2148510915.USD","688331","BK0239","LU2328871848.SGD","VXUS","LU1064130708.USD","LU1969619763.USD","BK4585","09995","BK1583","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173025596","title":"异动解读 | 荣昌生物盘中大涨5.17%，新药适应症获批及业绩扭亏为盈提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1173025596","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173025596?lang=zh_cn&edition=full","pubTime":"2026-04-15 10:25","pubTimestamp":1776219925,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大幅上涨，涨幅达到5.17%，引起了市场的广泛关注。消息面上，公司核心ADC药物维迪西妥单抗的一项新适应症近日获得国家药监局正式批准，用于联合特瑞普利单抗一线治疗HER2表达的局部晚期或转移性尿路上皮癌。该药物成为全球首个获批用于一线治疗晚期尿路上皮癌的HER2-ADC药物，标志着其治疗范围成功从后线拓展至一线，市场前景广阔。此外，公司基本面表现强劲，最新财报显示全年营收同比增长89.36%，成功实现扭亏为盈，净利润达到7.1亿元。近期，公司还获得了多家知名公募基金的密集调研，显示出机构投资者对其未来发展的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101505818","title":"荣昌生物2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1101505818","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101505818?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:16","pubTimestamp":1776158217,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年4月14日披露2026年3月股份变动月报表，报告期为2026年3月1日至3月31日。根据公告，该公司在香港联交所上市的H股及在上海证券交易所上市的A股在报告期内均无新增发行或回购注销，股本结构保持稳定。公司亦确认，截至报告期末，符合香港联交所相关上市规则之最低公众持股量要求。总体来看，荣昌生物2026年3月股本未发生任何实质变动，股本规模保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627349433","title":"4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627349433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627349433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:13","pubTimestamp":1776067998,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日荣昌生物涨7.98%，收盘报146.29元，换手率7.54%，成交量12.3万手，成交额17.51亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级10家；过去90天内机构目标均价为148.5。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共48家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300020025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688331","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","160916","BK1583","09995","LU1064130708.USD","BK1574","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627348834","title":"港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2627348834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627348834?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:02","pubTimestamp":1776045779,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物(09995)涨超4%，截至发稿，涨4.43%，报110.7港元，成交额2.35亿港元。消息面上，4月10日，荣昌生物宣布，公司自主研发的抗体偶联（ADC）药物维迪西妥单抗（RC48，爱地希®）一项新适应症获国家药品监督管理局正式批准上市，用于联合特瑞普利单抗治疗HER2表达的局部晚期或转移性尿路上皮癌患者，HER2表达定义为HER2免疫组织化学检查结果为1+、2+或3+。荣昌生物表示，这标志着维迪西妥单抗的治疗范围从后线成功拓展至一线，为中国HER2表达晚期尿路上皮癌患者带来了全新的治疗选择，也成为全球首个获批一线治疗晚期尿路上皮癌的HER2-ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU2148510915.USD","VXUS","09995","688331","BK4588","LU1969619763.USD","LU1064130708.USD","BK1583","LU1064131003.USD","LU2488822045.USD","BK4585","IPOS","BK1574","BK1161","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0392},{"period":"1month","weight":0.0501},{"period":"3month","weight":0.1948},{"period":"6month","weight":0.1178},{"period":"1year","weight":1.6439},{"period":"ytd","weight":0.3972}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}